Jialin Mao

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi Prediction of CYP3A-mediated drug-drug interactions using human hepatocytes suspended in human plasma
    Jialin Mao
    Department of Drug Disposition, Eli Lilly and Co Lilly Corporate Center, Indianapolis, IN 46285, USA
    Drug Metab Dispos 39:591-602. 2011
  2. ncbi Predictions of cytochrome P450-mediated drug-drug interactions using cryopreserved human hepatocytes: comparison of plasma and protein-free media incubation conditions
    Jialin Mao
    Drug Disposition, Lilly Research Laboratories, Eli Lilly and Co, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Drug Metab Dispos 40:706-16. 2012

Collaborators

Detail Information

Publications2

  1. ncbi Prediction of CYP3A-mediated drug-drug interactions using human hepatocytes suspended in human plasma
    Jialin Mao
    Department of Drug Disposition, Eli Lilly and Co Lilly Corporate Center, Indianapolis, IN 46285, USA
    Drug Metab Dispos 39:591-602. 2011
    ..Thus, HHSHP produced accurate DDI predictions with a simple IC(50) determined at a single incubation time regardless of the inhibition mechanism; further if needed, the mechanism(s) of inhibition can be identified...
  2. ncbi Predictions of cytochrome P450-mediated drug-drug interactions using cryopreserved human hepatocytes: comparison of plasma and protein-free media incubation conditions
    Jialin Mao
    Drug Disposition, Lilly Research Laboratories, Eli Lilly and Co, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Drug Metab Dispos 40:706-16. 2012
    ..In conclusion, the HHSHP system proved to be a simple, accurate predictor of DDIs for three major P450s and superior to the protein-free approach...